ES2072939T3 - Nuevos derivados de esteroides. - Google Patents

Nuevos derivados de esteroides.

Info

Publication number
ES2072939T3
ES2072939T3 ES90107415T ES90107415T ES2072939T3 ES 2072939 T3 ES2072939 T3 ES 2072939T3 ES 90107415 T ES90107415 T ES 90107415T ES 90107415 T ES90107415 T ES 90107415T ES 2072939 T3 ES2072939 T3 ES 2072939T3
Authority
ES
Spain
Prior art keywords
group
steroids
new derivatives
halogen atom
cycloalkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90107415T
Other languages
English (en)
Inventor
Teruo Komoto
Junji Okawa
Yoichiro Ogawa
Susumu Sato
Naokata Taido
Tadayuki Kuraishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Application granted granted Critical
Publication of ES2072939T3 publication Critical patent/ES2072939T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCUBREN DERIVADOS ESTEROIDES REPRESENTADOS POR LA FORMULA (I) EN DONDE R ES UN ATOMO DE HIDROGENO, UN ATOMO HALOGENO, UN GRUPO HIDROXILO, O UN GRUPO -OCOR1, EN DONDE R1 ES UN GRUPO ALQUILO LINEAL O RAMIFICADO EL CUAL PUEDE ESTAR SUSTITUIDO POR UN ATOMO HALOGENO O POR UN GRUPO CICLOALQUILO, UN GRUPO CICLOALQUILO, O UN GRUPO ARILO. LOS COMPUESTOS SE USAN PARA CURAR O ALIVIAR LA INFLAMACION O EL REUMATISMO.
ES90107415T 1989-04-19 1990-04-19 Nuevos derivados de esteroides. Expired - Lifetime ES2072939T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1099762A JPH07116215B2 (ja) 1989-04-19 1989-04-19 新規なステロイド化合物

Publications (1)

Publication Number Publication Date
ES2072939T3 true ES2072939T3 (es) 1995-08-01

Family

ID=14255990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90107415T Expired - Lifetime ES2072939T3 (es) 1989-04-19 1990-04-19 Nuevos derivados de esteroides.

Country Status (8)

Country Link
US (1) US5063222A (es)
EP (1) EP0393658B1 (es)
JP (1) JPH07116215B2 (es)
KR (1) KR950004901B1 (es)
CA (1) CA2014759C (es)
DE (1) DE69017938T2 (es)
ES (1) ES2072939T3 (es)
HK (1) HK125196A (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157594A1 (en) * 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
DE69722793T2 (de) * 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DK1274718T3 (da) * 2000-04-12 2007-02-12 Genaera Corp En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
PT1305329E (pt) * 2000-08-05 2007-12-24 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ATE396733T1 (de) * 2000-12-22 2008-06-15 Nippon Shinyaku Co Ltd Prophylaktische/therapeutische mittel für entzündliche atemwegserkrankungen
MY137522A (en) * 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
ES2307751T3 (es) * 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
KR101427467B1 (ko) * 2012-07-24 2014-08-08 경북대학교 산학협력단 아미노스테로이드 유도체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 항생제 조성물
CN112110972B (zh) * 2019-06-21 2022-03-18 河南利华制药有限公司 一种氯倍他索丙酸酯的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
SE418294B (sv) * 1974-03-27 1981-05-18 Plurichemie Anstalt Sett att framstella en 16alfa- eller 16beta-9alfa-klor eller -fluorsteroidester
JPS5855158B2 (ja) * 1975-06-16 1983-12-08 武田薬品工業株式会社 ステロイド誘導体の製造法
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes
US4021459A (en) * 1975-08-14 1977-05-03 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy 20-keto-pregnenes
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS52144664A (en) * 1976-05-25 1977-12-02 Takeda Chem Ind Ltd Steroid derivatives
DD134955A5 (de) * 1977-03-21 1979-04-04 Schering Ag Verfahren zur herstellung neuer derivate des 9-fluorprednisolons
DE2853785A1 (de) * 1978-12-11 1980-06-19 Schering Ag Neue prednison-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische praeparate und deren verwendung
IL66432A0 (en) * 1981-08-04 1982-12-31 Plurichemie Anstalt Process for the preparation of steroidal esters

Also Published As

Publication number Publication date
JPH02279694A (ja) 1990-11-15
KR950004901B1 (ko) 1995-05-15
KR900016251A (ko) 1990-11-13
EP0393658A3 (en) 1991-10-02
EP0393658A2 (en) 1990-10-24
JPH07116215B2 (ja) 1995-12-13
HK125196A (en) 1996-07-19
EP0393658B1 (en) 1995-03-22
US5063222A (en) 1991-11-05
CA2014759A1 (en) 1990-10-19
DE69017938D1 (de) 1995-04-27
CA2014759C (en) 2000-12-19
DE69017938T2 (de) 1995-11-16

Similar Documents

Publication Publication Date Title
ES2072939T3 (es) Nuevos derivados de esteroides.
SE7902794L (sv) Nya karbostyrilderivat och forfarande for framstellning derav
ES2051693T3 (es) Procedimiento para preparar compuestos biciclos de sulfonamida.
PY0101650A (es) 2-phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethyla-mine derivatives
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
DK1369409T3 (da) Fremgangsmåde til fremstilling af forbindelser, der er anvendelige som mellemprodukter
ATE42306T1 (de) 21-substituierte thiosteroide.
FR2357546A1 (fr) Derives de bis (4-aminopiperidine) utilisables pour stabiliser des matieres polymeres
FI862303A0 (fi) Foerfarande foer framstaellning av cancer motverkande kinazolinderivater.
ES2121256T3 (es) Benzoilguanidinas perfluoroalquilo-sustituidas, procedimiento para su preparacion, su uso como medicamento o agente de diagnostico, asi como medicamento que las contiene.
CO4950531A1 (es) Analogos de la vitamina d3 composciiones farmaceuticas que los contienen
AR005672A1 (es) Derivados de la distamicina, proceso para prepararlos, y su utilizacion como agentes antitumorales y antivirales.
ES2142763A1 (es) Derivados de 5'-desoxicitidina.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
AR241180A1 (es) Compuesto de benzisoxazol que incluye esteroisomeros del mismo y formulacion herbicida que lo contiene.
ES2037668T3 (es) Un procedimiento para la produccion de compuestos benzotiazolilazolidinas.
FI830893A0 (fi) Nya fenylpiperazin-derivat samt deras framstaellningsfoerfarande
ES418114A1 (es) Un procedimiento para la preparacion de nuevas 5-metiltio pirimidinas.
ES8306765A1 (es) "un procedimiento para preparar un derivado de antraciclina".
ES2063224T3 (es) Benzoxacinil-pirazoles, su produccion y su uso.
ES2038684T3 (es) Procedimiento de preparacion de derivados de octahidroindol y de compuestos intermedios de su preparacion.
ES2043639T3 (es) Procedimiento para la preparacion de azolil derivados fungicidas.
ES8504792A1 (es) Un procedimiento para preparar derivados de pirimidina
ES2059374T3 (es) Substancia 4181-2 y sus derivados.
ES8704460A1 (es) Un procedimiento para preparar derivados de 2-piridin-tiol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 393658

Country of ref document: ES